Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week.

[1]  A. Go,et al.  Analysis of Worsening Heart Failure Events in an Integrated Health Care System. , 2022, Journal of the American College of Cardiology.

[2]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[3]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.

[4]  J. Butler,et al.  Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. , 2022, Journal of cardiac failure.

[5]  G. Fonarow,et al.  Contextualizing Risk Among Patients With Heart Failure. , 2021, JAMA.

[6]  J. H. Patterson,et al.  Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry , 2021, Circulation. Heart failure.

[7]  G. Fonarow,et al.  Identifying Treatments for Stage C2 Heart Failure. , 2021, JAMA cardiology.

[8]  S. Solomon,et al.  Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. , 2021, JAMA cardiology.

[9]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[10]  Akshay S. Desai,et al.  Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial , 2021, The Lancet.

[11]  G. Filippatos,et al.  Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial , 2021, European heart journal.

[12]  Akshay S. Desai,et al.  Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial. , 2021, JACC. Heart failure.

[13]  G. Fonarow,et al.  Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[14]  G. Felker,et al.  Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States. , 2021, Journal of the American College of Cardiology.

[15]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[16]  P. Ponikowski,et al.  Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.

[17]  P. Ponikowski,et al.  Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.

[18]  S. Solomon,et al.  Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium , 2020, European journal of heart failure.

[19]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction , 2020, Circulation.

[20]  T. Biering-Sørensen,et al.  One‐Year Mortality After Intensification of Outpatient Diuretic Therapy , 2020, Journal of the American Heart Association.

[21]  G. Fonarow,et al.  Risk Profiles in Heart Failure , 2020, Circulation. Heart failure.

[22]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[23]  L. Lund,et al.  Congestion and Diuretic Resistance in Acute or Worsening Heart Failure , 2020, Cardiac failure review.

[24]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[25]  Mahesh J. Patel,et al.  Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. , 2019, Journal of the American College of Cardiology.

[26]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[27]  G. Felker,et al.  Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care , 2018, European journal of heart failure.

[28]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[29]  G. Felker,et al.  Outpatient Worsening Heart Failure as a Target for Therapy: A Review , 2018, JAMA cardiology.

[30]  S. Solomon,et al.  Pre‐discharge and early post‐discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial , 2018, European journal of heart failure.

[31]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[32]  H. Sabbah.  Silent disease progression in clinically stable heart failure , 2016, European journal of heart failure.

[33]  Akshay S. Desai,et al.  Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial. , 2016, JACC. Heart failure.

[34]  S. Solomon,et al.  Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). , 2016, Circulation.

[35]  M. Vaduganathan,et al.  The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.

[36]  E. Braunwald,et al.  Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. , 2014, JAMA.

[37]  K. Doran,et al.  Abstract 204: Emergency Department Visits for Heart Failure and Subsequent Hospitalization or Observation Unit Admission , 2014 .

[38]  W. Self,et al.  The burden of acute heart failure on U.S. emergency departments. , 2014, JACC. Heart failure.

[39]  S. Solomon,et al.  Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT‐CRT , 2014, European journal of heart failure.

[40]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[41]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.

[42]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[43]  Gerasimos Filippatos,et al.  Pathophysiologic targets in the early phase of acute heart failure syndromes. , 2005, The American journal of cardiology.